Literature DB >> 29454679

The prevalence and etiology of extreme hypertriglyceridemia in children: Data from a tertiary children's hospital.

Nivedita Patni1, Xilong Li2, Beverley Adams-Huet2, Abhimanyu Garg3.   

Abstract

BACKGROUND: Extreme hypertriglyceridemia (eHTG; serum triglycerides ≥ 2000 mg/dL) poses a significant risk for acute pancreatitis. There is paucity of data regarding the prevalence and etiology of eHTG in children.
OBJECTIVE: To determine the prevalence, clinical features and etiologies of patients with eHTG at a tertiary children's hospital in the United States and in the United States National Health and Nutrition Examination Survey (NHANES).
METHODS: A retrospective analysis was conducted of the electronic medical records of the Children's Medical Center, Dallas, from 2000-2015, and the NHANES data from 2005-2014 for eHTG.
RESULTS: Of 30,623 children, 36 (∼ 1 in 1000) had eHTG and one-third of them developed acute pancreatitis. They tended to be female (61%), Hispanic (39%), and nonobese (median body mass index z-score 1.60 and 1.25 in males and females, respectively). Most patients had secondary causes such as uncontrolled diabetes mellitus (30%), L-asparaginase and high-dose corticosteroid therapy for acute lymphoblastic leukemia (28%), and sirolimus/tacrolimus therapy after solid organ transplantation (14%). Five patients (14%) had type 1 hyperlipoproteinemia (T1HLP; familial chylomicronemia syndrome). The NHANES data revealed that none of the 2362 children had eHTG, and the prevalence in adults was 0.02%.
CONCLUSIONS: Extreme HTG is rare in children and majority of the children had secondary causes. Patients with diabetes mellitus or receiving drugs, such as, L-asparaginase, corticosteroids, and sirolimus, should be closely monitored for eHTG. Prevalence of T1HLP is approximately 1 in 6000 at a tertiary care center with an estimated population prevalence of 1 in 3,00,000. Early neonatal screening and intervention for T1HLP can prevent life-threatening morbidities such as acute pancreatitis.
Copyright © 2018 National Lipid Association. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Acute pancreatitis; Corticosteroid therapy; Extreme hypertriglyceridemia; Familial chylomicronemia syndrome; L-asparaginase therapy; Type 1 hyperlipoproteinemia; Uncontrolled diabetes mellitus

Mesh:

Year:  2018        PMID: 29454679     DOI: 10.1016/j.jacl.2018.01.003

Source DB:  PubMed          Journal:  J Clin Lipidol        ISSN: 1876-4789            Impact factor:   4.766


  7 in total

1.  Severe hypertriglyceridemia as a cause of necrotizing pancreatitis in a pediatric patient with familial hyperchylomicronemia syndrome: A case report.

Authors:  Laura Valenzuela-Vallejo; Daniela Meléndrez-Vásquez; Paola Durán-Ventura; Carolina Rivera-Nieto; Adriana Lema; Monica Fernandez
Journal:  SAGE Open Med Case Rep       Date:  2022-07-07

2.  Management strategy and novel ophthalmological findings in neonatal severe hypertriglyceridemia: a case report and literature review.

Authors:  Nehal M El-Koofy; Yasmeen A Abdo; Dina El-Fayoumi; Amanne F Esmael; Mohamed A Elmonem; Zahraa Ezzeldin
Journal:  Lipids Health Dis       Date:  2021-04-20       Impact factor: 3.876

3.  Identifying Patients with Familial Chylomicronemia Syndrome Using FCS Score-Based Data Mining Methods.

Authors:  Ákos Németh; Mariann Harangi; Bálint Daróczy; Lilla Juhász; György Paragh; Péter Fülöp
Journal:  J Clin Med       Date:  2022-07-25       Impact factor: 4.964

Review 4.  Haematological Drugs Affecting Lipid Metabolism and Vascular Health.

Authors:  Antonio Parrella; Arcangelo Iannuzzi; Mario Annunziata; Giuseppe Covetti; Raimondo Cavallaro; Emilio Aliberti; Elena Tortori; Gabriella Iannuzzo
Journal:  Biomedicines       Date:  2022-08-10

Review 5.  The Genetic Basis of Hypertriglyceridemia.

Authors:  Germán D Carrasquilla; Malene Revsbech Christiansen; Tuomas O Kilpeläinen
Journal:  Curr Atheroscler Rep       Date:  2021-06-19       Impact factor: 5.113

6.  Very Severe Hypertriglyceridemia in a Large US County Health Care System: Associated Conditions and Management.

Authors:  Maria Isabel Esparza; Xilong Li; Beverley Adams-Huet; Chandna Vasandani; Amy Vora; Sandeep R Das; Abhimanyu Garg; Zahid Ahmad
Journal:  J Endocr Soc       Date:  2019-05-20

Review 7.  A Comprehensive Update on the Chylomicronemia Syndrome.

Authors:  Ronald B Goldberg; Alan Chait
Journal:  Front Endocrinol (Lausanne)       Date:  2020-10-23       Impact factor: 5.555

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.